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Abstract
HER-2 is overexpressed in 20 to 30% of breast cancer. Generally, metastases of a breast tumor have
the same HER-2 status, although some discordances were reported.
We report a case of reduction in HER-2 expression assessed by immunohistochemistry, following
one day of a Trastuzumab injection, of a metastatic breast cancer to lymph nodes. Initially, the breast
tumor HER-2 status was positive according to the same technique.
We raise a hypothesis about technical interference and discuss the case in the framework of the
existing literature.
Introduction
HER-2 is a member of the ErbB family of transmembrane
growth factor receptors with tyrosine kinase activity.
Amplification of the HER-2 gene or overexpression of
the HER-2 protein is associated with adverse disease
prognosis and a worse response to treatment and has been
identified in 20-30% of primary breast carcinomas [1-3].
Its determination can be done by an immunohistochem-
ical (IHC) assay or fluorescence in situ hybridisation
(FISH) [4,5].
Trastuzumab is a humanized monoclonal anti-HER-2
antibody. Its efficacy is associated directly with the HER-2
status of the breast tumor. Indeed, the benefit of
trastuzumab is clearly limited to those patients with
HER-2 overexpression or amplification [6].
Generally, metastases of a breast tumor have the same
HER-2 status [7], although some discordances were
reported [8]. We report a case of reduction in HER-2
expression assessed by IHC, following one day of a
Trastuzumab injection, of a tumor which was positive
before according to the same technique raising a hypoth-
esis about technical interference
Case presentation
It is about a 66 year old Caucasian woman who presented
in 1982 a breast adenocarcinoma T2N0M0 treated by
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(page number not for citation purposes)lumpectomy and radiotherapy. In 1989, she presented a
rectal adenocarcinoma T4N0M0 treated by surgery.
Fifteen years later, the appearance of a left supra-clavicular
lymph node justified a biopsy showing metastases of
breast adenocarcinoma hormonal receptor negative and
HER-2 protein positive (expression was +++) assessed by
IHC. She had also infra and sub-diaphragmatic lymph
node involvement. A progression was noted after 4 cycles
of chemotherapy consisting of Docetaxel 75 mg/m
2
intravenously on day 1 and Doxorubicin 60 mg/m
2
intravenously on day 1 repeated every three weeks.
In order to exclude an associated rectal recurrence, a
biopsy of a retroperitoneal lymph node was programmed.
Monotherapy by Trastuzumab 4 mg/kg intravenously was
undertaken the day before biopsy. Anatomopathological
analysis with IHC confirms breast origin and shows
identical aspect with the left supra-clavicular lymph node
but the HER-2 status was negative (expression was only +).
Shortly after, the patient died due to progressive disease.
Discussion
In this case, the reduction in HER-2 protein expression can
not be explained by the elimination of expressing HER-2
clones, the patient having received only one injection of
Trastuzumab. Also, it can not be explained by chemother-
apy that received patient. It is currently known that
chemotherapy would not modify the HER-2 status in
metastatic lesions [7].
Tumor heterogeneity can be evoked. The main targets of
any therapy in metastatic breast cancer are the metastases.
However, in the great majority of cases, HER-2 status is
determined on the primary tumour, and there are few
published data regarding the comparison of HER-2 status
between the primary and the metastatic sites and between
multiple distant metastatic sites from the same patient and
all have reported a high level of consistency although not
complete [7-9]. The discordances can be explained by the
fact that in several of these studies, HER-2 status analysis
was made by IHC only. Another possible explanation may
be sample’s collection which could be done many years
before the present analysis, and therefore some protein
degradation might have occurred.
Tumor HER-2 status is generally assessed as protein
overexpression by IHC while HER-2 gene amplification
is detected by FISH and recently by CISH (Chromogenic in
situ hybridization) [10]. It is known that there is a high
level of correlation between FISH and IHC in the
evaluation of HER-2 status of breast cancers and thus, it
is not recommended to make a FISH analysis when HER-2
status is negative by IHC [11].
In our case, we raise a hypothesis about technical
interference related to the injection of Trastuzumab the
day before biopsy involving a reduction in HER-2 IHC
expression and thus we recommend, in such cases, to
make a study by FISH on the same biopsy which can
determine HER-2 status pertinently. This deserves to be
elucidated by studies with large series.
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